Corresponding cumulative incidences for endometrial cancer were 15.0% (95% CI (10.1–19.9)) versus 11.8% (95% CI (3.5–20.0)) for path_MLH1 carriers and 19.5% (95% CI (12.9–26.1)) versus 13.3% (95% CI (2.4–24.2)) for path_MSH2 carriers with truncating or missense/aberrant splicing variants, respectively. Here, MSH2 is linked to endometrial cancer.